MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable

Eduardo Vilar1, Catherine M Bartnik, Stephanie L Stenzel

  • 1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Cancer Research
|February 9, 2011
PubMed

Insights

Microsatellite instability (MSI) colorectal cancers with MRE11 mutations are sensitive to PARP-1 inhibitors. This suggests potential new treatments for MSI colorectal cancer (CRC) patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Microsatellite instability (MSI) occurs in ~15% of colorectal cancers (CRC).
  • Defective DNA mismatch repair can lead to mutations in double-strand break (DSB) repair genes like MRE11.
  • MRE11 mutations are correlated with MSI status in CRC cell lines and primary tumors.

Purpose of the Study:

  • To investigate the hypothesis that MRE11 deficiency sensitizes CRC cells to poly(ADP-ribose) polymerase-1 (PARP-1) inhibition.
  • To evaluate the efficacy of the PARP-1 inhibitor ABT-888 in CRC cell lines with varying MRE11 mutational status and MSI.
  • To experimentally validate the role of MRE11 in conferring sensitivity to PARP-1 inhibition.

Main Methods:

  • Assessed MRE11 mutational status in 17 CRC cell lines and 46 primary tumors.
  • Administered PARP-1 inhibitor ABT-888 to CRC cell lines and measured cytotoxicity.
  • Utilized short hairpin RNA (shRNA) to knockdown MRE11 in a wild-type/microsatellite-stable (MSS) cell line (SW-480).
  • Transfected a cell line with mutant MRE11 to create a second experimental model.

Main Results:

  • Found a strong correlation between MRE11 mutational status and MSI in CRC.
  • Observed preferential cytotoxicity to ABT-888 in MSI CRC cell lines with MRE11 mutations.
  • Demonstrated a significant correlation between MRE11 expression levels and ABT-888 cytotoxicity (R² = 0.915, P < 0.001).
  • Experimental models showed proliferation changes in response to ABT-888, but a clear drug-response effect was not consistently observed, suggesting additional genetic factors.

Conclusions:

  • MSI colorectal tumors with MRE11 deficiency exhibit heightened sensitivity to PARP-1 inhibition.
  • MRE11 mutations may represent a predictive biomarker for PARP-1 inhibitor therapy in CRC.
  • Further clinical investigation of PARP-1 inhibitors in MSI CRCs is warranted.

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...